Prostate-specific antigen screening, a procedure designed to detect prostate cancer, recently received a failing grade from the U.S. Preventive Services Task Force. That report has weighed on Intuitive Surgical's (NASDAQ:ISRG) growth, because PSA screenings have been a large driver of prostatectomies, one of the company's flagship procedures. In this video, Motley Fool health care analyst Brenton Flynn dives into the impact this trend is having on the company and where it might find growth in other areas.